The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characterizing fatigue associated with sunitinib (SU) in patients (pts) with metastatic renal cell carcinoma (mRCC).
David Cella
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Mellar P. Davis
Consultant or Advisory Role - Pfizer (U)
Andrew G. Bushmakin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Joseph C Cappelleri
Employment or Leadership Position - Pfizer
Elizabeth A Hahn
Consultant or Advisory Role - Pfizer
Beata Korytowsky
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Helen Bhattacharyya
Stock Ownership - Pfizer
Rickard Sandin
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Jennifer L Beaumont
Research Funding - Pfizer
Ewa Matczak
Employment or Leadership Position - Pfizer
Stock Ownership - Pfizer
Robert John Motzer
Consultant or Advisory Role - Pfizer
Research Funding - AVEO; GlaxoSmithKline; Novartis; Pfizer